Monatepil
Appearance
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Names | |
---|---|
Preferred IUPAC name
N-(6,11-Dihydrodibenzo[b,e]thiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider |
|
KEGG |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C28H30FN3OS | |
Molar mass | 475.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Chemical compound
Monatepil is a calcium channel blocker and α1-adrenergic receptor antagonist used as an antihypertensive.[1]
Synthesis
The synthesis of monatepil was first disclosed in patents filed by Dainippon Pharmaceutical.[2]
The amino group of the dihydrodibenzothiepin (1) is first reacted with the acid chloride of 4-chlorobutyric acid, to give the amide (3). This is then used to alkylate para-fluorophenylpiperazine (4) to yield monatepil.[2][3]
References
- ^ Sugimoto T, Hosoki K, Karasawa T (July 1995). "Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil". Journal of Cardiovascular Pharmacology. 26 (1): 55–60. doi:10.1097/00005344-199507000-00009. PMID 7564365. S2CID 1548014.
- ^ a b US patent 4749703, Hitoshi Uno, et al., "Calcium antagonist piperazine derivatives, and compositions therefor", issued 1988-06-07, assigned to Dainippon Pharmaceutical Co Ltd
- ^ Kurokawa, Mikio; Sato, Fuminori; Fujiwara, Iwao; et al. (1991). "A new class of calcium antagonists. 2. Synthesis and biological activity of 11-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyryl]amino]-6,11-dihydrodibenzo[b,e]thiepin maleate and related compounds". Journal of Medicinal Chemistry. 34 (3): 927–934. doi:10.1021/jm00107a009. PMID 2002473.
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
---|---|---|---|---|---|
Other antagonists |
| ||||
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
α1 |
| ||||
---|---|---|---|---|---|
α2 |
| ||||
β |
| ||||
Classes | |
---|---|
Antidepressants (Tricyclic antidepressants (TCAs)) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Anticholinergics | |
Others |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |